COMBINATION IBRUTINIB (IBR) AND VENETOCLAX (VEN) FOR THE TREATMENT OF MANTLE CELL LYMPHOMA (MCL): PRIMARY ENDPOINT ASSESSMENT OF THE PHASE 2 AIM STUDY

Saved in:
Bibliographic Details
Published in:Hematological oncology 2017-06, Vol.35 (S2), p.144-145
Main Authors: Tam, C.S., Roberts, A.W., Anderson, M., Dawson, S., Hicks, R., Burbury, K., Turner, G., Di Iulio, J., Bressel, M., Westerman, D., Agarwal, R., Pott, C., Dreyling, M., Dawson, M., Seymour, J.F.
Format: Article
Language:English
Subjects:
Lymphoma
Mantle
Mantle cell lymphoma
Targeted cancer therapy
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:
ISSN:0278-0232
1099-1069
DOI:10.1002/hon.2437_134